Fulgent Genetics Q3 Revenues More Than Double; Raises FY21 Outlook

  • Fulgent Genetics Inc FLGT reported Q3 sales of $227.9 million, +124% Y/Y, beating the consensus of $264 million primarily driven by sales of its COVID-19 tests.
  • Fulgent said that the billable tests delivered in the quarter grew to approximately 2.2 million, up from 1.04 million in Q3 2020.
  • Excluding COVID-related testing, the firm's core revenues increased almost fourfold, to $40.1 million.
  • Fulgent's third-quarter results significantly exceeded the firm's quarterly guidance for both core and COVID-19 revenues, Chairman and CEO Ming Hsieh said in a statement.
  • Adjusted EPS doubled to $4.05, beating the consensus of $3.25.
  • Fulgent finished Q3 with $214.9 million in cash and cash equivalents and $662.4 million in marketable securities.
  • Guidance: For Q4 FY21, Flugent expects revenues of approximately $189 million (consensus $171.20 million), with core revenues of roughly $32 million.
  • For FY21, it expects revenue of $930 million, up from its previous guidance of $800 million but lower than the consensus of $948 million.
  • Price Action: FLGT shares are up 1.82% at $80.05 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!